References
- Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Sun, Ophthalmol. 2002;47:1–16.
- Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukocyte Biol.2002;71:907–920.
- French LE, Hahne M, Viard L, Radlgruber G, Zanone R, Becker K, Muller C, Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune privileged tissues and co-expression in adult tissues characterized by apoptotic cell turn over. J Cell Biol. 1996;133:335–343.
- Griffith TS, Fergusen TA. The role of Fas L-induced apoptosis in immune privilege. Immunol Today. 1997;18:240–244.
- Yonehara S, Ishii A,Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169:1747–1756.
- Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–1178.
- Walker PR., Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 1998;10: 564–572.
- Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA.1995;92:5436–5440.
- Gallie BL, Philips RA, Ellsworth RM, Abramson DH. Significance of retinoma and pthisis bulbi for retinoblastoma. Ophthalmology. 1982;89:1393–1399.
- Nambu Y, Hughes SJ, Rehemtula A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102–1110.
- Mottolese M, Buglioni S. Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 2000;89:127–132.
- Ito Y, Takeda T, Umeshita K, Sakon M, Wakasa K, Matsuura N, Monden M. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep. 1998;5:41–44.
- Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocelllar carcinoma and noncancerous tissues. Am J Pathol. 1996;149:429–437.
- Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, Krammer PH. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994;57: 371–377.
- Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J. Oncogenic Ras inhibits Fas ligand mediated apoptosis by down regulating the expression of Fas. Eur Mol Biol Organ (EMBO) J. 1999; 18: 1824–1831.
- Volkmann M, Schiff JH, Hajjar Y, Otto G, Stilgenbauer F, Fiehn W, Galle PR, Hofmann WJ. Loss of CD 95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med. 2001;79:594–600.
- Hettinger C, Kurz E, Bohler T, Schrappe M, Ludwig WD, Debatin KM. CD 95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:3943–3951.
- Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ. Alteration of Fas (APO-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999 ; 18 :3754–3760.
- Stannard C, Lipper S, Sealy R, Sevel D. Retinoblastoma: correlation of invasion of the optic nerve and choroid with prognosis and metastasis. Br J Ophthalmol. 1979;63:560–570.
- Kopelman JE, McLean 1W, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 1987;94:371–377.